Axonics Modulation Technologies, Inc. announced that it received a Homologation d'un instrument médical (medical device approval) for the first rechargeable Sacral Neuromodulation (r-SNM™) System to treat Overactive Bladder (OAB), Fecal Incontinence and Urinary Retention. The Health Canada license confirms that the Axonics product meets all of the Canadian Medical Devices Regulations, Section 36, for Active Implantable Medical Devices and enables Axonics to market its r-SNM System throughout Canada. The Axonics r-SNM System is an implantable neuromodulation system that modulates sacral nerve activity for the management of urinary and fecal dysfunction. The System includes, among other innovations, a miniaturized implantable pulse generator that is 60% smaller than currently marketed non-rechargeable SNM technology and promises to last at least 15 years. In addition, the Axonics r-SNM System features a key-fob sized patient-friendly remote control and an intuitive clinician programmer that will guide and support physician implanters throughout the procedure, from lead placement to programming.